Clinical Trials
184
28 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1949
Completed
111
60.3%
Not yet recruiting
28
15.2%
Recruiting
41
22.3%
Suspended
1
0.5%
Unknown
1
0.5%
No approval data available
- A study of 275 Omicron-era long COVID patients found that lower SARS-CoV-2 spike antibody levels were significantly associated with memory impairment, a hallmark of brain fog. - Nucleocapsid antibody levels reflected infection-related factors such as disease severity and time since infection, declining approximately 0.34% per day in unvaccinated patients. - Higher spike antibody levels correlated with better self-reported quality of life, suggesting antibody profiles may help predict neurological complications in long COVID. - Researchers from Okayama University propose that viral antibody titers could serve as objective biomarkers to aid prognosis and guide personalized care for post-COVID conditions.
- Researchers from Okayama University and CNRS developed charge-reversible graphene oxide nanomaterials that remain undetected in neutral blood pH but become positively charged in acidic tumor environments. - The optimized GOPGNH60-DMMA variant demonstrated superior tumor cell uptake while avoiding healthy tissue binding, confirmed through mouse model studies. - This breakthrough in pH-responsive nanomedicine provides concrete guidelines for improving targeted drug delivery and opens new avenues for theranostic applications combining cancer diagnosis and treatment.
- A Japanese study of 27 patients with drug-resistant migraine found that 81% experienced significant improvement or complete resolution after transcatheter patent foramen ovale closure at 12 months. - Patients with migraine with aura showed particularly strong responses, with 48% achieving complete resolution compared to only one patient without aura experiencing full relief. - The procedure was completed successfully without complications in all cases, though the study acknowledges limitations including lack of a control group and potential selection bias. - Despite previous large-scale trials in the US and Europe failing to confirm efficacy, these findings suggest PFO closure may benefit carefully selected patients with refractory migraine, particularly those with aura.
- Researchers found that higher levels of anti-PD-1 autoantibodies in blood serum correlate with lower survival rates in HCC patients undergoing Atezolizumab/Bevacizumab therapy. - The study suggests anti-PD-1 autoantibody levels could serve as a potential biomarker for predicting the efficacy of immune checkpoint inhibitors in HCC treatment. - This non-invasive method offers a way to identify patients less likely to respond to Atezo/Bev, potentially guiding more personalized treatment strategies. - The findings may pave the way for developing improved treatment regimens for liver cancer by predicting the efficacy of immune checkpoint inhibitors.
